Breast cancer is the most common type of cancer diagnosed in woman in the Western world. While earlier detection and better treatment has improved survival rates, women with a history of breast cancer are still at risk for recurrence for the rest of their lives and need regular monitoring.
No single serum marker is sensitive enough for diagnosis of breast cancer. However, for monitoring and follow-up, use of tumor markers are an established part of routine clinical management. Clinical studies demonstrate that the activity marker assay, TPS® provides valuable information about tumor cell activity.
Cytokeratins act as prognostic markers, indicators of metastatic disease, and as markers for recurrence of breast cancer. High levels of cytokeratins almost certainly indicate the spread of disease in the body.
In therapy monitoring, TPS® shows a high sensitivity for progressive disease. Furthermore, TPS® decreases in short time to normal levels if therapy is successful, whereas traditional volume markers remain elevated for a longer period. TPS® and the widely-used marker CA 15-3 are an effective combination for patient monitoring.
About Breast Cancer:
Prior to the introduction of mammography screening, breast cancer was diagnosed by a lump in the breast. Mammography screening has significantly increased awareness for women and resulted in earlier detection of breast cancer.
Today, prognosis for breast cancer is generally good with an estimated average five-year survival rate over 70 percent. Medical data also indicates that breast cancer mortalities have declined in recent years.